Everest Medicines today announced that China’s National Medical Products Administration (NMPA) has approved CARDAMYST(R) (etripamil) for the conversion of acute symptomatic episodes of paroxysmal...
Everest Medicines (HKG: 01952) announced its interim results for the six months ended June 30, 2026. Everest delivered strong growth and reached an important...
Everest Medicines (HKEX 1952.HK) announced the closing of its previously announced exclusive licensing and collaboration agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX) for the...
June 26, 2026, Everest Medicines today announced that China’s National Medical Products Administration (NMPA) accepted the Biologics License Application (BLA) for LEROCHOL(R) (lerodalcibep), a...
Everest Medicines (HKEX 1952.HK) announced that Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui's budesonide enteric capsules,...
Everest Medicines (HKEX 1952.HK)announced that it has entered into an exclusive licensing agreement with Australia Dimerix Limited (Dimerix), for the development and commercialization of...
Everest Medicines (HKEX 1952.HK) announced that it has entered into a commercialization license agreement with Beijing Mabworks Biotech Co., Ltd. (Mabworks), under which the...
